Technology ID
TAB-4936
Modification and Optimization of HIV Neutralizing Antibodies for Improved Therapeutic and Vaccinogenic Efficacy
E-Numbers
E-131-2012-0
Lead Inventor
Nabel, Gary
Lead IC
NIAID
Co-Inventors
Mascola, John
Zhou, Tongqing
ICs
NIAID
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Discovery
Research Products
Plasmids/Vectors
Human Cell Lines
Antibodies
The technology pertains to the enhancement of HIV neutralizing antibodies, specifically VRC01, VRC07, and 10E8, which have been isolated and characterized for their potent antiviral activity. These antibodies have undergone specific mutations to improve their breadth and potency against a range of HIV strains. The aim is to extend their half-life, augment their in vivo effectiveness, and reduce immunogenicity. These modifications could lead to more effective therapeutic applications and inform the design of HIV vaccines, with potential incorporation into various vectors like AAV or adenovirus, and DNA expression vectors. This discovery stage technology holds promise for advancing HIV treatment and prevention methodologies.
Commercial Applications
The enhanced HIV neutralizing antibodies could revolutionize therapeutic strategies for HIV, offering new avenues for treatment with increased efficacy and reduced side effects. They hold promise for long-acting HIV prevention methods, potentially simplifying pre-exposure prophylaxis regimens. In vaccine development, these antibodies can serve as templates to design vaccines that elicit robust and broad immune responses. Furthermore, the technology could be adapted for diagnostic purposes, aiding in the precise detection of diverse HIV strains. These applications underline the technology's versatility, with the potential to make significant impacts across various healthcare settings and patient populations.
Competitive Advantages
This novel modification of HIV neutralizing antibodies offers competitive advantages by enhancing their breadth and potency against a diverse array of HIV strains, exceeding the capabilities of current antiviral agents. The mutations enhance antibody stability and half-life, reducing the frequency of administration and improving patient compliance. Additionally, these antibodies are designed to be less immunogenic, which minimizes adverse reactions and makes them suitable for a broader patient population. The adaptability of these antibodies for integration into different delivery vectors also positions this technology at the forefront of therapeutic innovation, potentially streamlining the path toward both prophylactic and therapeutic vaccine development.
Licensing Contact: